acr-23 Encodes a monepantel-sensitive channel in Caenorhabditis elegans
- PMID: 23950710
- PMCID: PMC3738477
- DOI: 10.1371/journal.ppat.1003524
acr-23 Encodes a monepantel-sensitive channel in Caenorhabditis elegans
Abstract
Monepantel is a member of the recently identified class of anthelmintics known as the amino-acetonitrile derivatives (AADs). Monepantel controls all major gastro-intestinal nematodes in sheep including those that are resistant to the classical anthelmintics. Previous studies have shown that the Caenorhabditis elegans acr-23 and the Haemonchus contortus Hco-mptl-1 genes may be prominent targets of monepantel. With this discovery it became possible to investigate the mode of action of monepantel in nematodes at the molecular level. In the present study, we show that a C. elegans mutant acr-23 strain is fully rescued by expressing the wild-type acr-23 gene. Moreover, we present a new mutant allele, and characterize acr-23 alleles genetically. We also show that acr-23 is expressed in body wall muscle cells, and provide therefore a possible explanation for the paralysis caused by monepantel. Furthermore, genetic evidence suggests that the chaperone RIC-3 is required for expression of full monepantel resistance. Finally, we present reconstitution of the C. elegans ACR-23 receptor in Xenopus laevis oocytes and provide direct evidence of its modulation by monepantel. Conversely, co-injection of the chaperone RIC-3 had no impact for channel reconstitution in X. laevis oocytes. These results reinforce the involvement of the ACR-23 family in the mode of action of monepantel and advance our understanding of this new class of anthelmintics.
Conflict of interest statement
I have read the journal's policy and have the following conflicts: LR and JB authors are currently under the employment of Novartis Animal Health, which provided funds and equipment to conduct part of the studies and where they receive salary, benefits and stock. This does not alter our adherence to all PLoS Pathogens policies on sharing data and materials. Monepantel has been developed at Novartis Animal Health. The use of AADs for veterinary purposes is patented (WO2002049641).
Figures
References
-
- Waller PJ, Rudby-Martin L, Ljungstrom BL, Rydzik A (2004) The epidemiology of abomasal nematodes of sheep in Sweden, with particular reference to over-winter survival strategies. VetParasitol 122: 207–220. - PubMed
-
- Kaminsky R, Ducray P, Jung M, Clover R, Rufener L, et al. (2008) A new class of anthelmintics effective against drug-resistant nematodes. Nature 452: 176–180. - PubMed
-
- Rufener L, Keiser J, Kaminsky R, Maser P, Nilsson D (2010) Phylogenomics of ligand-gated ion channels predicts monepantel effect. PLoS Pathog 6: e1001091 doi:10.1371/journal.ppat.100109 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
